Multiplex Analysis of Proteins (MAP)
Director: Laurent RENIA, Ph.D.
Using advanced technology, the SIgN MAP facility offers a high-throughput, simultaneous screening service of protein targets/analytes from a single sample at sample volumes as low as 25ul.
Multiplexing methods are commonly used in the screening of potential biomarkers in large clinical cohorts and immunomonitoring research applications. Integrated with the SIgN Immunomonitoring Platform, we provide an one-stop solution to ease the lives of our researchers by maximizing sample data value from precious clinical samples while saving time and money.
Technologies and Approach
One of the main technology that we use is the Luminex® xMAP® technology. It is a bead-based multiplexed immunoassay system in a microplate format, which allows researchers to simultaneously quantify analytes/biomarkers in a single 25ul sample. This technology combines advanced fluidics, optics, and digital signal processing with proprietary microsphere technology to deliver multiplexed assay capabilities. xMAP® beads are internally labeled with different intensities of two fluorophores. Target-specific proteins such as antibodies and nucleic acids can be coupled to these beads. Each bead or bead region is coated/coupled with a capture antibody for one specific target. Multiple-analyte specific beads are then combined in single well, before detecting and quantifying by Luminex® analyzer FLEXMAP 3D®. Using a dual laser system, bead region is identified at 635nm excitation and reporter dye detected at 532nm at the same time. This provides information on both bead signature and analyte concentrations in the sample. The incorporation of DropArray™ technology also enables a great reduction in multiplex cost and volumes of valuable clinical samples used.